BioAge Labs (BIOA) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed BioAge Labs (BIOA) over the past year, losing 26.7% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $196.5 million), about 1.0 times the size. BioAge Labs converts more of its revenue into profit, with a net margin of -896.1% versus -4646.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | YARW |
|---|---|---|
| Share price | $4.28 | $12.90 |
| Market cap | $196.67M | $196.53M |
| 1-day change | -9.13% | -9.35% |
| YTD return | -67.65% | -55.52% |
| 1-year return | -50.52% | -26.70% |
| 5-year return | — | -98.61% |
| EPS (TTM) | $-2.56 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.99M | $570.00K |
| Revenue growth (YoY) | — | +13.77% |
| Net income (latest FY) | $-80.61M | $-26.48M |
| Operating margin | -1031.46% | -5219.12% |
| Net margin | -896.11% | -4646.14% |
| 52-week high | $25.96 | $46.95 |
| 52-week low | $4.24 | $12.39 |
| Distance from 52-week high | -83.51% | -72.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +572.43% | +310.85% |
| Average volume | 740.06K | 153.34K |
| Shares outstanding | 45.95M | 15.23M |
| Employees | 60 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed BIOA by 23.8 percentage points over the past year.
- BioAge Labs is more profitable, keeping -896.1 cents of every revenue dollar as net income versus -4646.1 cents for Yarrow Bioscience.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BIOA vs YARW FAQ
Which is bigger, BioAge Labs or Yarrow Bioscience?
BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $196.53M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, BIOA or YARW?
YARW returned -26.70% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.